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ABSTRACT
Objective: Human papilloma virus (HPV) is the world’s most common causative agent in sexually
transmitted viral infections; thus requiring clinical guidance, before and after treatment, to promote
better quality of life in women diagnosed with HPV. The HPV Impact Profile (HIP) is a comprehensive
instrument used to assess the psychosocial impact of HPV and related interventions in a wide range
of domains. The main purpose of this study was to validate the HIP in Portuguese women, so that it
can be used in this population, both in research and in clinical settings.
Methods: A sample of 178 Portuguese women infected with HPV were assessed with the following
instruments: Index of Sexual Satisfaction, Hospital Anxiety and Depression Scale and HPV
Impact Profile.
Results: The results of the confirmatory factor analysis showed some changes to the original model,
which resulted in an adapted version with six domains, compared to the seven domains of the ori-
ginal model. The final model showed a good fit to the data. All Cronbach’s alphas were higher than
0.79 indicating a high level of internal consistency of the subscales. As in the original HIP question-
naire, the exception was sexual impact, with a lower, but acceptable, Cronbach’s alpha. Convergent
and discriminant validities of the instrument were also assessed.
Conclusions: The Portuguese version of the HIP presents good psychometric properties, allowing its
use in clinical trials as well as in clinical practice in order to evaluate quality of life in women
with HPV.
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The human papilloma virus (HPV) is a sexually transmitted
virus that is lodged in mucous membranes or even on the
skin, affecting both men and women. According to the
American Centers for Disease Control and Prevention1, HPV
is the world’s most common causative agent in sexually
transmitted viral infections. According to the WHO there are
2.784 million women 15 years old or over at risk of develop-
ing cervical cancer (CC). According to current estimates,
every year, 527.624 women are diagnosed with this type of
cancer, while 265.672 die from the disease2.
In Portugal, CC is considered the second most frequent
gynecological malignant tumor in Portuguese women under
50. Moreover, between 2011 and 2015 this country showed a
decrease in both incidence and mortality rate by CC3. The
most common high-risk HPV types, 16 and 18, are associated
with carcinoma, while type 6 and 11 are the most persistent
in benign and premalignant lesions4. HPV represents a public
health problem given the high prevalence of the infection
leading to cancer, with the additional factor that the
diagnosis carries a negative psychosocial impact on the
patient’s life5.
A qualitative study has revealed that an HPV diagnosis
can cause two types of reaction in women: negative and
positive. Negative impact concerns reactions such as shame
or stigma, while the positive impact relates to reactions such
as relief and happiness6. Also, studies show that both the
clinical examinations and treatment cause suffering, anxiety
and reduced quality of life (QoL)7,8. Additionally, patients
diagnosed with genital warts and diseases related to HPV
have reported a negative impact on their psychosocial well-
being and QoL9.
The diagnosis of a sexually transmitted infection (STI) and
its treatment have a negative impact not only on women,
but also on their marital relationship10. Factors such as fear
of infection, and physical and psychosocial discomfort
regarding the treatment were found to influence the sexual
life of HPV-infected women and of their partners11. Upon
receiving the diagnosis, many women cease wanting sexual
intercourse while others reduce their activity11. The psycho-
logical, emotional and negative interpersonal aspects of hav-
ing HPV are more relevant for sexual adjustment than the
characteristics of the infection itself12. Additionally, women
with an STI are not merely aware of these social stigmas:
they internalize them, reporting reduced sexual satisfaction
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compared to men13. A study conducted at eleven hospitals
including women diagnosed with HPV found a greater con-
cern about sexuality and a negative impact in different
stages of the infection, compared to the general popula-
tion14. On the other hand, sexually satisfied women, having
positive sexual self-esteem and an active sexual life, experi-
ence reduced anxiety when confronted with the diagnosis/
treatment of HPV12. Results may be related to how much
they are satisfied with their own relationship and with the
communication within the relationship itself, as these factors
moderate the impact of an HPV diagnosis related to sexual
wellbeing and QoL12.
HPV infection is associated with anxiety, depression, fear of
developing CC15,16 and worse QoL17,18. In addition, the ever-
present concern associated with ongoing examinations, inva-
sive and painful treatments, and consultations which increase
in case of relapses, contribute even further to women’s vulner-
ability regarding both emotional and sexual wellbeing19.
Psychosexual counseling is a key aspect to prevent further
negative psychosexual results during the treatment of HPV-
related lesions20, in order to provide better clinical guidance,
before and after treatment, and to promote a better QoL21.
The existing instruments that assess QoL in the presence
of HPV are scarce. Thus, finding measures capable of assess-
ing QoL associated with the health and the psychological
impact of HPV is not only needed, but also relevant in order
to design interventions that can meet the patients’ needs
within clinical practice22. Therefore, there is a need for instru-
ments to assess the impact of this infection.
The HPV Impact Profile (HIP) was the first HPV-specific
questionnaire able to assess, at once, a broader spectrum of
HPV-related disease or conditions, including genital warts23.
This instrument includes 29 items and aims at assessing the
psychosocial impact of HPV in the following seven domains:
1 – worries and concerns; 2 – emotional impact; 3 – sexual
impact; 4 – self-image; 5 – partner issues and transmission; 6
– interactions with doctors; 7 – control/life impact. Potential
uses of this questionnaire include general research about
HPV (e.g. study of evolution trends about the psychosocial
impact of the HPV and analysis of predictors associated with
higher psychosocial burden), as well as clinical settings, help-
ing clinicians to identify impaired domains and, as such, to
promote better QoL in this population.
The purpose of this study was to adapt the HIP23 to
Portuguese women with HPV. This instrument has already
been validated in Mandarin Chinese in order to avoid spell-
ing and grammar mistakes, and wording errors, while pre-
serving the original version and guaranteeing its cultural
adequacy. It was applied as a pilot test24. However, the
authors have not reported psychometric properties for this
Chinese version. Therefore, to the best of our knowledge,
this is the first HIP validation study in a foreign language.
2. Methods
2.1. Participants
The sample included 178 women with HPV who were receiv-
ing treatment in two major public hospitals in the Northern
Region of Portugal. Criteria for inclusion were: (i) adult
women, with an HPV diagnosis; (ii) having a sexual partner.
Exclusion criteria included being pregnant or having
another STI.
2.2. Instruments
2.2.1. HPV Impact Profile
This questionnaire aims to assess the psychosocial impact
of HPV infection23. It is made up of 29 items that are div-
ided into seven domains: Worries/Concerns (e.g. “I am wor-
ried about having abnormal Pap test results”); Emotional
Impact (e.g. “When I think about my recent gynecology
exam or test results, I feel anxious”); Sexual Impact (e.g.
“After my recent gynecology exam or test results, I am
having less sex”); Self-Image (e.g. “When I think about my
recent gynecology exam or test results, I feel my body is
sexually attractive”); Partner/Transmission (e.g. “After my
recent gynecology exam or test results, I am worried that
having sex with my partner may give him/her and
infection”); Interaction with Doctors (e.g. “I felt my recent
gynecology procedures were embarrassing”); and Health
Control/Life Impact (e.g. “After my recent gynecology exam
or test results, I feel I can concentrate as well as usual on
everyday matters”). Answers are provided on a Likert scale
ranging from zero (Not at all) to ten (Extremely). The rank-
ing of each domain is calculated through the sum of its
items, divided by the number of items of the domain,
multiplied by ten. The same formula is valid to calculate
the total score. Higher scores indicate worse QoL.
2.2.2. Index of Sexual Satisfaction
This instrument is a 25-item unidimensional scale with the
purpose of assessing the level of sexual satisfaction in a
marital relationship (e.g. “Our sex life is very exciting” and
“My partner seems to avoid sexual contact with me”)25.
Answers are provided on a Likert scale ranging from one
(Never feel) to seven (Always feel). Higher results indicate
higher levels of sexual dissatisfaction.
2.2.3. Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS)26 assesses
psychological morbidity in patients with physical pathologies
in outpatient treatment. It is made up of 14 items, divided
into two subscales: Anxiety (e.g. “I get a sort of frightened
feeling as if something awful is about to happen”) and
Depression (e.g. “I get sudden feelings of panic”). Scores
range from 0 to 21 for both subscales. Higher scores indicate
higher levels of psychological distress.
2.3. Procedure
This study used a cross-sectional design. Data was collected
in two hospitals in the Northern Region of Portugal, namely,
Hospital of Braga and Hospital of Santa Luzia (ULSAM). The
study was approved by the Portuguese Data Protection
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Authority (CNPD) and by each hospital’s ethics committee.
Patient identification was carried out by each patient’s gyne-
cologist who invited them if they fulfilled the inclusion crite-
ria. In the diagnostic appointment, all women having a
positive HPV result were informed by the gynecologist about
the infection, including the specific HPV type. HPV type was
then used to group patients into only two categories: low
risk or high risk.
All patients were duly informed regarding the nature of
the study itself, data confidentiality and voluntary participa-
tion, signing informed consent. All invited patients accepted
to take part in this study. All data was collected in paper for-
mat and stored securely in locked file cabinets.
2.4. Sample characteristics
The sample included 178 women with HPV, ages ranging
from 21 to 63 (M¼ 39, SD¼ 9.85). Participants’ education var-
ied considerably, from 2 to 17 years. More specifically, 45.5%
of the sample had at most nine school years, 36.5% attended
a secondary school (10–12 years) and 18.0% had a university
degree. The mean number of years of schooling is large
(10.15) and so this sample is highly educated. Regarding
marital status, 43.3% of participants were married. In this
sample, 42.1% presented a high-risk HPV diagnosis. Table 1
presents the sample characterization.
2.5. Data analysis
Descriptive analyses were used to describe the sociodemo-
graphic and clinical characteristics of HPV women. A con-
firmatory factor analysis (CFA) was applied to the Portuguese
version of the HIP23. The HIP questionnaire was applied in a
survey with 178 Portuguese women.
The CFA was performed using the structural equation
modeling (SEM) technique, following the main recommenda-
tions presented by Brown27. The observed variables were
analyzed as continuous data28. The robust ML estimator was
used to compute non-normality robust standard errors and
chi-square, through a scaling correction factor for the
Satorra–Bentler method29. Reliability of the latent variables
was assessed using Cronbach’s alpha and composite reliabil-
ity CR30, with CR >.7 suggesting good factor reliability31.
Convergent validity and discriminant validity were inspected
using the average variance extracted30 and the
Heterotrait–monotrait (HTMT) ratio of correlation criterion32.
According to Hu and Bentler33 and Kline34, good model fit is
indicated by a ratio chi-square over the number of degrees
of freedom smaller than 3, CFI, TLI and RNI values “close to”
.95 (or higher), RMSEA values “close to” .06 (or smaller), and
SRMS values “close to” .08 (or smaller).
Statistical analyses were performed using the R statistical
environment RStudio, version 3.4.3,35, through “lavaan” pack-
ages36 and “semTools”37.
2.6. Construct validity
Mast et al. grouped the 29 items from the HIP23 into the fol-
lowing seven hypothesized domains (asterisks denote reverse
scores): Domain 1 – Worries/Concerns (Items 7, 12, 13, 15,
16, 17, 18, 19, 20); Domain 2 – Emotional Impact (Items 2, 3,
5, 8, 14); Domain 3 – Sexual Impact (Items 24, 25); Domain
4 – Self-Image (Items 1, 10, 11, 23), Domain 5 – Partner/
Transmission (Items 9, 21, 22), Domain 6 – Interaction with
Doctors (Items 27, 28, 29); Domain 7 – Health Control/Life
Impact (Items 4, 6, 26). The adequacy of this item division
to the sample of this study was explored. Extremely similar
wordings were observed for items 21 and 22 in the
Portuguese version and, thus, the corresponding residual cor-
relation was included in the model.
As summarized in Table 2, applied to this study’s sample,
the model revealed poor reliability, validity problems and
poor fitting to the data. Therefore, a new item division was
developed based on both an exploratory factor analysis and
a theoretical understanding of the literature review. This con-
fluence between theory and statistics allowed the following
six hypothesized domains to be obtained: Domain 1 –
Worries/Concerns (Items 3, 7, 12, 13, 15, 16, 17, 20), Domain
2 – Emotional Impact (Items 2, 5, 8, 26), Domain 3 – Sexual
Impact (Items 9, 24, 25), Domain 4 – Future Treatment/
Transmission (Items 18, 19, 21, 22), Domain 5 – Positive
Emotions (Items 1, 4, 6, 10, 14, 27), Domain 6 –
Negative Emotions (Items 11, 23, 28, 29).
A CFA was conducted to confirm the effectiveness of this
factorial division. As before, the same residual correlation
due to very similar wordings was added to the model. In
general, this model presented good reliability and acceptable
convergent validity (AVE values lower than the .5 threshold
are indeed very close to this limit). Nevertheless, all the con-
sidered goodness-of-fit indices lay outside the recommended
range, as summarized in Table 2.
The model fit was improved by removing all items with
small factor loadings (less than .4). This procedure led to the
elimination of six items out of 29, namely items 7, 11, 12, 13,
20 and 26. Table 2 also presents the results of the CFA
applied to the reduced model, with 23 indicators, which is
depicted in Figure 1.
Table 1. Sociodemographic characterization of women with HPV (N¼ 178).
Continuous measure Min Max Mean SD







Married/common law union 57.9
Partner 40.4
HPV type
Type 6/11 low risk 57.9
Type 16/18 high risk 42.1
Duration of treatment 24.2
Low risk, short HPV duration 33.7
Low risk, long HPV duration 17.4
High risk, short HPV duration 24.7
High risk, long HPV duration
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3. Results
3.1. Reliability
As observed in Table 2, all six domains showed good construct
reliability. Each domain exhibited acceptable Cronbach’s alpha
(from .69 to .86), good composite reliability and acceptable
average variance extracted (only two values bordering below
the .5 threshold). Goodness-of-fit measures are within the rec-
ommended range and thus good fit is achieved.
3.2. Goodness-of-fit measures
The results revealed a good adjustment of this model to the
data: chi-square¼ 296.27; df¼ 214; CFI¼ .951; TLI¼ .943;
Table 2. Results of the confirmatory factor analysis.
Validity/reliability measures
Model Factor Alpha CR AVE Fitting measures (scaled versions)
Original HPV model
(Mast et al.23)






90% CI ¼ .100
SRMR ¼ .97
Emotional Impact 2, 3, 5, 8, 14 0.8 0.8 0.45
Sexual Impact 24, 25 0.74 0.74 0.59
Self-Image 1, 10, 11, 23 0.76 0.76 0.47
Partner/Transmission 9, 21, 22 0.66 0.54 0.33
Interaction with Doctors 27, 28, 29 0.69 0.77 0.56
Health Control/Life Impact4, 6, 26 0.66 0.66 0.44
Total 0.93 0.96 0.5







90% CI ¼ .095
SRMR ¼ .111
Emotional Impact 2, 5, 8, 26 0.81 0.81 0.52
Sexual Impact 9, 24, 25 0.69 0.7 0.48
Future Treatment/Transmission 18, 19, 21, 22 0.86 0.85 0.61
Positive Emotions 1, 4, 6, 10, 14, 27 0.83 0.84 0.48
Negative Emotions 11, 23, 28, 29 0.76 0.79 0.55
Total 0.93 0.96 0.52







90% CI ¼ .056
SRMR ¼ .076
Emotional Impact 2, 5, 8 0.79 0.79 0.55
Sexual Impact 9, 24, 25 0.69 0.71 0.48
Future Treatment/Transmission 18, 19, 21, 22 0.86 0.85 0.61
Positive Emotions 1, 4, 6, 10, 14, 27 0.83 0.84 0.48
Negative Emotions 23, 28, 29 0.83 0.85 0.71
Total 0.92 0.96 0.57
Abbreviations. CR, Composite reliability; AVE, Average variance extracted; CFI, Comparative fit index; TLI, Tucker–Lewis Index; RNI, Relative noncentrality index;
RMSEA, Root–mean–square error of approximation; SRMR, Standardized root mean square residual.
Asterisks denote reverse scores.
Figure 1. The final structural equation model for the HIP, fitting for Portuguese women diagnosed with HPV. Ellipses are the latent constructs (factors or scales)
and rectangles are the indicators (items). All values are standardized parameter estimates. Solid lines represent significant relationships and the dashed line denotes
a non-significant residual covariance. For clarity, errors of endogenous variables are not shown, but were included in the analysis.
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RNI¼ .966; RMSEA¼ .046; RMSEA upper 90%
CI¼ .056; SRMR¼ .076.
3.3. Discriminant validity
The Heterotrait–monotrait (HTMT) ratio of correlations criter-
ion32 was used to establish the discriminant validity. This
type of validity is used to guarantee that indicators of theor-
etically distinct constructs are not highly intercorrelated27.
The HTMT matrix (Table 3) shows the discriminant validity of
the model according to the HTMT criterion, as no entry
exceeds the common prescribed cutoff of 0.8532. Comparing
the HIP with the other two instruments (HADS and ISS), the
discriminant validity was established, as before, through the
HTMT matrix (Table 3), using the same argument.
3.4. Convergent validity
Convergent validity is indicated by evidence that different
indicators of theoretically similar or overlapping constructs are
strongly interrelated27. Convergent validity was established
between the scales of HIP and psychological morbidity (HADS)
and sexual satisfaction (ISS). Results are summarized in Table 4
and values greater than .5 were taken as evidence of conver-
gent validity38,39. As expected, among all HIP domains, the
strongest relationship of ISS was observed for Sexual Impact,
and the strongest relationship of HADS was observed for
Emotional Impact. ISS was also associated with the depreci-
ation of Positive Emotions, and HADS was also related to both
Sexual Impact and depreciation of Positive Emotions.
3.5. Differences in quality of life according to HPV type
and women’s education level
Quality of life showed differences according to the type of
HPV (t [176]¼5.161, p < .001). Women with high-risk HPV
reported worse QoL when compared to those with low-risk
HPV. However, there were no differences in QoL according to
the women’s level of education (F [3, 174] ¼.662, p ¼. 576).
4. Discussion
The purpose of this study was the validation of the HIP23
in a sample of Portuguese women diagnosed with HPV.
The original scale includes 29 items and seven domains.
Cronbach alphas were .90 for Worries/Concerns, .77 for
Emotional Impact, .64 for Sexual Impact, .82 for Self-Image,
.82 for Partner/Transmission, .69 for Interaction with Doctors
and .71 for Health Control/Life Impact. In the present study,
the CFA produced a final model with 23 items and six
domains. Cronbach alphas were .86 for Worries/Concerns
(with four items), .79 for Emotional Impact (with three items),
.69 for Sexual Impact (with three items), .86 for Future
Treatment/Transmission (with four items), .83 for Positive
Emotions (with six items) and .83 for Negative Emotions
(with three items). Therefore, when comparing the Cronbach
alphas obtained in this study with the original version one
finds they are relatively better, which demonstrates a high
degree of internal consistency.
Compared with the original model, this study presents a
first domain with the same name (Worries and Concerns),
having removed six items (7, 12, 13, 18, 19 and 20), and
included item 3, thus composing a final domain with four
items. Items 7, 12, 13 and 20 were removed from the final
model due to low factor loadings (below .4), granting a bet-
ter model fit. In addition, particularly in this first domain,
items 12 and 13 concerning worries about “genital warts”
may not have been saturated because 81% of women
claimed to have no lesions associated with HPV, and were
therefore “not worried” about it. Nevertheless, undergoing
pelvic examinations, Pap smear in particular, generates dis-
comfort, fear and concern40.
In this study, the second domain maintains the name
Emotional Impact, but left out item 3 (saturated in the first
domain) and item 14 (saturated in the fifth domain).
Consequently, this domain was left with three items. Flynn
and collaborators41 report that women diagnosed with HPV
experience a certain emotional impact upon diagnosis, often
feeling anxiety and shame.
Regarding the Sexual Impact domain, this study added
only item 9. Thus, the domain consisted of three items and
maintained the same name. In general, items describe the
sexual impact on women after the Pap smear, as well as a
negative impact on marital relationships. Faced with a diag-
nosis and treatment of cervical dysplasia, women develop a
sense of loss of control over their bodies, anxiety regarding
their personal and genital health, compromising their body
image and self-esteem, sexual life and marital adjustment,
with an impact on sexual well-being17.
The fourth domain of this study comprises four items (18,
19, 21 and 22). It was named Future Treatment/Transmission
due to item saturation and according to the semantics of the
content within them, which deal with the fear of developing
Table 3. The HTMT ratio of correlations for the six-factor final model depicted
in Figure 1, and the HADS and ISS scales.




F4 .849 .692 .507
F5 .638 .749 .713 .549
F6 .275 .399 .414 .303 .418
HADS .390 .667 .538 .362 .599 .331
ISS .195 .334 .772 .175 .435 .347 .564
Abbreviations. F1, Worries/Concerns; F2, Emotional Impact; F3, Sexual Impact;
F4, Future Treatment/Transmission; F5, Positive Emotions; F6, Negative
Emotions; HADS, Hospital Anxiety and Depression Scale; ISS, Index of Sexual
Satisfaction.
Table 4. Correlations between the HIP subscales and both the HADS and
ISS measures.
Factor F1 F2 F3 F4 F5 F6
HADS .389 .661 .533 .371 .597 .357
ISS .161 .324 .756 .096 .429 .362
Abbreviations. F1, Worries/Concerns; F2, Emotional Impact; F3, Sexual Impact;
F4, Future Treatment/Transmission; F5, Positive Emotions; F6, Negative
Emotions; HADS, Hospital Anxiety and Depression Scale; ISS, Index of Sexual
Satisfaction. Bold values are significant at (p < .05).
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CC and concerns about transmitting the infection. In fact,
HPV diagnosis, being significantly associated with anxiety,
entails additional concerns for patients regarding sexual
intercourse, decreasing sexual activity and fear of developing
CC. In addition to these concerns, women feel guilt, fear and
anguish when receiving a positive HPV result42,43.
The fifth domain refers to positive emotions (all items in
this factor are reverse scored) and is made up of six items.
As such, it was named Positive Emotions, since the semantics
of the content focuses on women’s positive feeling after the
examination and feeling good about themselves. Thornton
et al.44 studied patients diagnosed with breast or gyneco-
logic cancers and found that, in contrast to the great
negativity observed, they were able to experience positive
emotions which provided information on their own cop-
ing strategies.
The last domain of this study refers to negative emotions
and consists of three items (23, 28 and 29). Thus, this sixth
domain was named Negative Emotions due to item satur-
ation and semantics. The content addresses issues about
women feeling sick, embarrassed and uncomfortable. An
HPV diagnosis affects self-esteem and sexual satisfaction,
generating frustration, embarrassment, annoyance and dis-
comfort, influencing women’s QoL20,42,43.
Despite the differences regarding the domains and com-
posing items, the final model presents a good fit to the data.
With regard to convergent validity, this study used the
Index of Sexual Satisfaction (ISS) instrument, per the predic-
tion that QoL domains, namely Sexual Impact, were related
to sexual satisfaction within the conjugal context. The
internal consistency of this questionnaire is very high and,
more precisely, Cronbach alpha in the original version was
.93, .95 in the Portuguese version and .96 in this study. As
expected, among all the HIP domains, ISS was strongly
related to the Sexual Impact domain, together with a depre-
ciation in Positive Emotions. The Hospital Anxiety and
Depression Scale (HADS) was also used in this study and it
evidenced convergent validity with the following HIP sub-
scales: Emotional Impact, Sexual Impact and Positive
Emotions. This convergence indicates that the HIP domains
are strongly related to women’s depression and anxiety. The
literature suggests that the different stages of diagnosis and
treatment of HPV infection may have different impacts on
women and on couples45, with negative effects on sexual
health and QoL throughout time46. Moreover, the literature
also reports that an HPV positive result causes a negative
impact on women’s psychosocial and emotional lives, trig-
gering feelings such as hopelessness, anger, fear, anxiety and
depression47. Patients with lesions associated with HPV see
their sexuality affected, thus experiencing a negative impact
on their QoL9,48.
Discriminant validity was also demonstrated, showing that
all HIP subscales were not highly correlated, either between
themselves or with the ISS and HADS scales. This latter
instrument showed high internal consistency: in the original
version alphas were .85 for anxiety and .81 for depression; in
the Portuguese version they were .76 and .81, respectively;
and in this research, alphas were .91 and .88, respectively. In
this study, only the total scale was used. Among all the HIP
domains, HADS was strongly related to the Emotional Impact
domain. In addition to this association, HADS was related to
both the Sexual Impact domain and a depreciation in posi-
tive emotions. When receiving an abnormal result in their
Pap smear, women experience psychological distress, which
causes a negative emotional impact, thus influencing their
QoL49. In fact, women experience a strong emotional impact
when receiving an HPV diagnosis50, with stigma and nega-
tive emotions51 such as anxiety, depression, anguish and
concerns16,52. This is because it precedes CC, regardless of a
positive or negative result53. Furthermore, there is an
increased negative psychological burden due to the infec-
tion’s relapse rates, causing concern and anxiety in women54.
This study found that women with high-risk HPV (types 16/
18) reported worse QoL than the low-risk ones. This result is
in accordance with the literature that shows that when receiv-
ing a high-risk HPV diagnosis, patients experience greater suf-
fering due to higher anxiety and fear of developing CC55.
Additionally, STIs trigger conjugal, emotional, psychological
and sexual consequences for women56. This study found no
differences concerning participants’ education level on QoL,
probably because this sample is highly homogenous and
highly educated. In the literature, the studies have mixed
results. There are studies reporting that women with higher
levels of education are more aware of the infection, which
lessens their anxiety57,58 and improves their QoL. Conversely,
the study by Daley and collaborators51 found that women
with higher levels of education reported more negative emo-
tions (anxiety/depression/fear). Hence, future studies should
replicate these results in samples with women with lower
education levels and assess the role of education on QoL.
This study had some underlying limitations: the sample
was highly educated and there was a predomination of
women with low-risk HPV. Consequently, future studies
should include less educated women. It will also be import-
ant to evaluate the relationship between women’s QoL and
their partners’ QoL, taking into account the type of HPV and
the duration of the diagnosis.
In brief, the model outlined in Figure 1 with six latent
constructs was applied to a sample of Portuguese women
with HPV and showed goodness of fit, as well as good con-
struct reliability and internal consistency. Convergent and
discriminant validity were also established. These good psy-
chometric properties give HIP the capacity to assess the psy-
chosocial impact of HPV and related interventions in a wide
range of domains in the Portuguese population. In particular,
this instrument is of utmost importance in the HPV field, not
only for future research studies, but also for clinical purposes.
Indeed, clinicians may also apply HIP to identify QoL
domains that need intervention and to promote better QoL
in this population.
5. Conclusions
The results of this study show the importance of assessing
psychosocial factors in women dealing with an HPV diagno-
sis. The HIP presents good psychometric qualities, showing
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good convergent validity, with significant associations with
sexual satisfaction, along with good divergent validity
regarding psychological morbidity (anxiety/depression). The
confirmatory analysis revealed that the model presented
good goodness-of-fit measures. The Portuguese version
includes six domains (Worries/Concerns, Emotional Impact,
Sexual Impact, Future Treatment/Transmission, Positive
Emotions and Negative Emotions), being a relevant tool to
be used in clinical trials, as well as in clinical practice, in
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